LIDDS AB (publ) announces that the company will implement significant cost containment measures to maximise the runway for business development and potential license agreements without the need for further financing. These measures mean that further investments in clinical development will be held back until licensing agreements can be secured. Redundancies in the company's personnel will also be considered.

Given the significant decrease in company operations caused by this decision, the Board has reached an agreement with CEO, Anders MÃ¥nsson, which means that he will work part-time as CEO until end August, and after that he will leave the company to pursue other opportunities. LIDDS's management, board and Alira Health will continue to work on the licensing projects until a result is reached. There are several interested stakeholders in the process, and LIDDS must ensure that a potential negotiation is not impaired by the time constraints of diminishing cash and the need to re-finance mid-process.